Series B · Medtech & Devices · Ulm, Germany · Founded 2015 · 130–140 employees
NVision Quantum Technologies is a Ulm-based deeptech company pioneering quantum technologies for healthcare, having developed POLARIS — a quantum-enhanced hyperpolarization platform that boosts MRI signals from sugar-based imaging agents by orders of magnitude, enabling real-time metabolic imaging on standard MRI systems to assess cancer treatment response within hours rather than months. The company is expanding beyond quantum sensing into quantum computing with its new PIQC (Photonic Integrated Quantum Circuits) platform, built on a novel class of organic molecule-based qubits integrated directly onto photonic chips, targeting drug design and therapy validation. In May 2026, NVision closed a $55 million Series B anchored by Abbott, including a $17 million EIB venture loan, bringing total capital raised to $120 million. POLARIS systems are already being deployed at world-leading cancer centres including Memorial Sloan Kettering, University of Cambridge, and TU Munich, with ~20 installations expected globally by end of 2026.